A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Overview of attention for article published in Neuro-Oncology, April 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#47 of 3,556)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

blogs: 1 blog
twitter: 139 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 70 Dimensions

Readers on

mendeley: 71 Mendeley

Summary Blogs X Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

Bibliosalut, 15 Apr 2021

#PublicaSalutIB Continuació de la temozolomida adjuvant més enllà de 6 cicles en pacients amb glioblastoma https://buff.ly/3doLRZ…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.